Merus N.V. Share Price
NASDAQ: MRUSMerus N.V. Stock Performance
Open N/A | Prev. Close N/A | Circuit Range N/A |
Day Range N/A | Year Range N/A | Volume N/A |
Average Traded N/A |
Merus N.V. Share Price Chart
Merus N.V. Stock Fundamentals & Key Indicators
Market Cap N/A | PE Ratio (TTM) N/A | Dividend Yield N/A |
EPS (TTM) $-3.00 | Revenue (TTM) $43.95M | Return On Equity (TTM) N/A |
Profit Margin -352.56% | Debt to Equity N/A | Quarterly Earnings Growth YoY -216.17% |
Merus N.V. Quarterly Profit & Loss
All figures in USD
Merus N.V. Annual Profit & Loss
All figures in USD
About Merus N.V.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Merus N.V. Historical Returns
| Month | Open | Close | Change % |
|---|
MRUS Share Price FAQs
What is Merus N.V. share price today?
What is the 52 week high and 52 week low of Merus N.V. stock?
What is MRUS's net income for the last quarter?
Can I buy MRUS shares in India?